Dalfampridine in patients with downbeat nystagmus—an observational study

Claassen, Jens; Feil, Katharina; Bardins, Stanislav; Teufel, Julian; Spiegel, Rainer; Kalla, Roger; Schneider, Erich; Jahn, Klaus; Schniepp, Roman; Strupp, Michael (2013). Dalfampridine in patients with downbeat nystagmus—an observational study. Journal of neurology, 260(8), pp. 1992-1996. Springer-Medizin-Verlag 10.1007/s00415-013-6911-5

Preview

Text Dalfampridine2013_Neurology.pdf - Published Version Available under License Publisher holds Copyright. Download (249kB) | Preview

We investigated the effects of dalfampridine, the sustained-release form of 4-aminopyridine, on slow phase velocity (SPV) and visual acuity (VA) in patients with downbeat nystagmus (DBN) and the side effects of the drug. In this proof-of-principle observational study, ten patients received dalfampridine 10 mg bid for 2 weeks. Recordings were conducted at baseline, 180 min after first administration, after 2 weeks of treatment and after 4 weeks of wash-out. Mean SPV decreased from a baseline of 2.12 deg/s ± 1.72 (mean ± SD) to 0.51 deg/s ± 1.00 180 min after first administration of dalfampridine 10 mg and to 0.89 deg/s ± 0.75 after 2 weeks of treatment with dalfampridine (p < 0.05; post hoc both: p < 0.05). After a wash-out period of 1 week, mean SPV increased to 2.30 deg/s ± 1.6 (p < 0.05; post hoc both: p < 0.05). The VA significantly improved during treatment with dalfampridine. Also, 50 % of patients did not report any side effects. The most common reported side effects were abdominal discomfort and dizziness. Dalfampridine is an effective treatment for DBN in terms of SPV. It was well-tolerated in all patients.

Interest & Impact

Downloads

87 since deposited on 23 Jun 2014
55 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item